ArticleAnnals of the New York Academy of Sciences2026
tRF-30-FP18LPMBQ4NK in Systemic Juvenile Idiopathic Arthritis: A Promising Diagnostic and Disease Activity Biomarker.
Article in Annals of the New York Academy of Sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diagnosing systemic juvenile idiopathic arthritis (sJIA) poses significant challenges. Accumulating evidence has indicated that tRNA-derived fragments (tRFs) play integral roles in the pathogenesis of numerous diseases. Plasma samples were collected from individuals diagnosed with sJIA and healthy controls (HCs) from two medical centers and divided into training and validation cohorts. Small-RNA high-throughput sequencing was employed to investigate the expression profiles of tRFs in the plasma of patients. Aberrantly expressed tRFs in sJIA were validated using quantitative reverse-transcription PCR (qRT-PCR). A total of 245 tRFs were differentially expressed in sJIA samples than in HC samples. Through qRT-PCR validation, tRF-30-FP18LPMBQ4NK was identified as a potential biomarker. In the training cohort, plasma levels of tRF-30-FP18LPMBQ4NK were significantly higher in patients with sJIA than in HCs. Furthermore, the tRF-30-FP18LPMBQ4NK levels in patients in the active disease group were substantially higher than those in the inactive disease group. Additionally, the positive and negative predictive values of the selected tRF in the validation cohort reached 100% and 85%, respectively. Our results suggest that tRF-30-FP18LPMBQ4NK can be used as a promising biomarker candidate for sJIA and has the potential to aid in determining disease activity among patients with sJIA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.